Development of nanosuspension formulation for oral delivery of quercetin

Journal of Biomedical Nanotechnology

Volumn 6, Issue 4, 2010, Pages 325-332

  Sun, Min ^a   Gao, Yan ^a   Pei, Yan ^a   Guo, Chenyu ^a   Li, Houli ^b   Cao, Fengliang ^a   Yu, Aihua ^a   Zhai, Guangxi ^a  

^a SHANDONG UNIVERSITY   (China)

^b UNIVERSITY OF TEXAS AT AUSTIN   (United States)

Author keywords

Bioavailability; High pressure homogenization; Nano precipitation; Nanosuspension; Quercetin

Indexed keywords

BIOAVAILABILITY; HIGH PRESSURE HOMOGENIZATION; NANO-PRECIPITATION; NANOSUSPENSION; QUERCETIN;

BIOCHEMISTRY; FATTY ACIDS; HOMOGENIZATION METHOD; PHENOLS; SCANNING ELECTRON MICROSCOPY; SPHERES; TRANSMISSION ELECTRON MICROSCOPY; X RAY DIFFRACTION; ZETA POTENTIAL;

DISSOLUTION;

NANOPARTICLE; PHOSPHATIDYLCHOLINE; QUERCETIN; DRUG; MACROGOL DERIVATIVE; PEO PPO PEO; PEO-PPO-PEO; PROPANEDIOL DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; BINDING AFFINITY; CELL MEMBRANE; CONTROLLED STUDY; DISSOLUTION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DESIGN; DRUG FORMULATION; DRUG SOLUBILITY; ELECTROPHORESIS; ENCAPSULATION; HIGH PRESSURE HOMOGENIZATION; MAXIMUM PLASMA CONCENTRATION; MEMBRANE PERMEABILITY; MORPHOLOGY; NANOPRECIPITATION; NANOSUSPENSION; NONHUMAN; PARTICLE SIZE; PRECIPITATION; RAT; SCANNING ELECTRON MICROSCOPY; TECHNIQUE; TIME TO MAXIMUM PLASMA CONCENTRATION; TRANSMISSION ELECTRON MICROSCOPY; X RAY DIFFRACTION; ZETA POTENTIAL; ANIMAL; BIOAVAILABILITY; CHEMICAL STRUCTURE; CHEMISTRY; MALE; METHODOLOGY; NANOTECHNOLOGY; ORAL DRUG ADMINISTRATION; SOLUBILITY; SUSPENSION; WISTAR RAT;

ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL AVAILABILITY; CHEMISTRY, PHARMACEUTICAL; MALE; MICROSCOPY, ELECTRON, TRANSMISSION; MOLECULAR STRUCTURE; NANOTECHNOLOGY; PHARMACEUTICAL PREPARATIONS; POLYETHYLENE GLYCOLS; PROPYLENE GLYCOLS; QUERCETIN; RATS; RATS, WISTAR; SOLUBILITY; SUSPENSIONS;

EID: 79952999641     PISSN: 15507033     EISSN: 15507041     Source Type: Journal    
DOI: 10.1166/jbn.2010.1133     Document Type: Article

References (52)

1. A. Dolenc, J. Kristl, S. Baumgartner, and O. Planinšek, Advantages of celecoxib nanosuspension formulation and transformation into tablets. Int. J. Pharm. 376, 204 (2009).
2. M. Kakran, N. G. Sahoo, L. Li, Z. Judeh, Y. Wang, K. Chong, and L. Loh, Fabrication of drug nanoparticles by evaporative precipitation of nanosuspension. Int. J. Pharm. 383, 285 (2010).
3. C. M. Keck and R. H. Müller, Drug nanocrystals of poorly soluble drugs produced by high pressure homogenization. Eur. J. Pharm. Biopharm. 62, 3 (2006).
4. G. G. Liversidge and P. Conzentino, Drug particle size reduction for decreasing gastric irritancy and enhancing absorption of naproxen in rats. Int. J. Pharm. 125, 309 (1995).
5. S. Ganta, J. W. Paxton, B. C. Baguley, and S. Garg, Formulation and pharmacokinetics evaluation of an asulacrine nanocrystalline suspension for intravenous delivery. Int. J. Pharm. 367, 179 (2000).
6. M. A. Kassem, A. A. A. Rahman, M. M. Ghorab, M. B. Ahmed, and R. M. Khalil, Nanosuspension as an ophthalmic delivery system for certain glucocorticoid drugs. Int. J. Pharm. 340, 126 (2007).
7. C. Jacobs and R. H. Muller, Production and characterization of abudesonide nanosuspension for pulmonary administration. Pharm. Res. 19, 189 (2002).
8. M. G. L. Hertog, E. J. M. Feskens, D. Kromhout, M. G. L. Hertog, P. C. H. Hollman, and M. B. Katan, Dietary antioxidant flavonoids and risk of coronary heart disease: The zutphen elderly study. The Lancet. 342, 1007 (1993).
9. P. C. Hollman and M. B. Kata, Dietary flavonoids: Intake, health effects and bioavailability. Food Chem. Toxicol. 37, 937 (1999).
10. M. Yoshida, T. Sakai, N. Hosokawa, N. Marui, K. Matsumoto, A. Fujioka, H. Nishino, and A. Aoike, The effect of quercetin on cell cycle progression and growth of human gastric cancer cells. FEBS Lett. 260, 10 (1990).
11. A. Orzechowski, K. Grzelkowska, W. Zimowska, J. Skierski, T. Ploszaj, K. Bachanek, T. Motyl, W. Karlik, and M. Filipecki, Induction of apoptosis and NF-κB by quercetin in growing murine L1210 lymphocytic leukaemic cells potentiated by TNF-alpha. Reprod. Nutr. Dev. 40, 441 (2000).
12. J. A. Choi, J. Y. Kim, J. Y. Lee, C. M. Kang, H. J. Kwon, Y. D. Yoo, T. W. Kim, Y. S. Lee, and S. J. Lee, Induction of cell cycle arrest and apoptosis in human breast cancer cells by quercetin. Int. J. Oncol. 19, 837 (2001).
13. J. Jakubowicz-Gil, J. Rzymowska, and A. Gawron, Quercetin, apoptosis, heat shock. Biochem. Pharmacol. 64, 1591 (2002).
14. M. Kaneuchi, M. Sasaki, Y. Tanaka, N. Sakuragi, S. Fujimoto, and R. Dahiya, Quercetin regulates growth of Ishikawa cells through the suppression of EGF and cyclinDl. Int. J. Oncol. 22, 159 (2003).
15. E. Cheong, K. Ivory, J. Doleman, M. L. Parker, M. Rhodes, and I. T. Johnson, Synthetic and naturally occurring COX-2 inhibitors suppress proliferation in a human oesophageal adeno-carcinoma cell line (OE33) by inducing apoptosis and cell cycle arrest. Carcinogenesis 25, 1945 (2004).
16. P. C. Kuo, H. F. Liu, and J. L. Chao, Survivin and p53 modulate quercetin-induced cell growth inhibition and apoptos is in the human lung carcinoma cells. J. Biol. Chem. 279, 55875 (2004).
17. T. T. Nguyen, E. Tran, T. H. Nguyen, P. T. Do, T. H. Huynh, and H. Huynh, The role of activated MEK-ERK pathway in quercetin-induced growth inhibition and apoptosisin A549 lung cancer cells. Carcinogenesis 25, 647 (2004).
18. C. S. Ong, E. Tran, T. T. Nguyen, C. K. Ong, S. K. Lee, J. J. Lee, C. P. Ng, C. Leong, and H. Huynh, Quercetin-induced growth inhibition and cell death in nasopharyngeal carcinoma cells are associated with increase in Badand hypophosphorylated retinoblastoma expressions. Oncol. Rep. 11, 727 (2004).
19. K. A. Khaled, Y. M. El-Sayed, and B. M. Al-Hadiya, Disposition of the tavonoid quercetin in rats after single intravenous and oral doses. Drug Dev. Ind. Pharm. 29, 397 (2003).
20. R. Gugler, M. Leschik, and H. J. Dengler, Disposition of quercetin in man after single oral and intravenous doses. Eur. J. Clin. Pharmacol. 9, 229 (1975).
21. Y. Gao, Y. Q. Wang, Y. K. Ma, A. H. Yu, F. Q. Cai, W. Shao, and G. X. Zhai, Formulation optimization and in situ absorption in rat intestinal tract of quercetin-loaded microemulsion. Colloids Surf., B 71, 306 (2009).
22. H. L. Li, X. B. Zhao, Y. K. Ma, G. X. Zhai, L. B. Li, and H. X. Lou, Enhancement of gastrointestinal absorption of quercetin by solid lipid nanoparticles. J. Controlled Release 133, 238 (2009).
23. Y. Hu, H. L. Chen, and W. Q. Liang, Preparation and quality evaluation of quercetin self-emulsifyied drug delivery systems. China J. Chin. Mater. Medic. 32, 805 (2007).
24. E. Alexopoulou, A. Georgopoulos, K. A. Kagkadis, and C. Demetzos, Preparation and characterization of lyophilized liposomes with incorporated quercetin, J. Liposome Res. 16, 17 (2006).
25. A. Priprem, J. Watanatorn, S. Sutthiparinyanont, W. Phachonpai, and S. Muchimapura, Anxiety and cognitive effects of quercetin liposomes in rats. Nanomedicine 4, 70 (2008).
26. Y. Zheng and A. H. Chow, Production and characterization of a spray-dried hydroxypropyl-beta-cyclodextrin quercetin complex. Drug Dev. Ind. Pharm. 35, 727 (2009).
27. K. V. Sri, A. Kondaiah, J. V. Ratna, and A. Annapuma, Preparation and characterization of quercetin and rutin cyclodextrin inclusion complexes. Drug Dev. Ind. Pharm. 33, 245 (2007).
28. M. E. Ribeiro, I. G. Vieira, I. M. Cavalcante, N. M. Ricardo, D. Attwood, S. G. Yeates, and C. Booth, Solubilisation of griseofulvin, quercetin and rutin in micellar formulations of triblock copolymers E62P39E62 and E137S18E137. Int. J. Pharm. 378, 211 (2009).
29. O. Kayser, C. Olbrich, V. Yardley, A. F. Kiderlen, and S. L. Croft, Formulation of amphotericin B as nanosuspension for oral administration. Int. J. Pharm. 254, 73 (2003).
30. Y. Gao, S. Qian, and J. Zhang, Physicochemical and pharmacokinetic characterization of a spray-dried Cefpodoxime proxetil nanosuspension. Chem. Pharm. Bull. 58, 912 (2010).
31. B. Rabinow, J. Kipp, P. Papadopoulos, J. Wong, J. Glosson, J. Gass, C. S. Sun, T. Wielgos, R. White, C. Cook, K. Barker, and K. Wood, Itraconazole IV nanosuspension enhances efficacy through altered pharmacokinetics in the rat. Int. J. Pharm. 339, 251 (2007).
32. K. Baba, H. E. Pudavar, I. Roy, T. Y. Ohulchanskyy, Y. Chen, R. K. Pandey, and P. N. Prasad, New method for delivering a hydrophobic drug for photodynamic therapy using pure nanocrystal form of the drug. Mol. Pharm. 4, 289 (2006).
33. D. Douroumis and A. Fahr, Nano- and micro-particulate formulations of poorly water-soluble drugs by using a novel optimized technique. Eur. J. Pharm. Biopharm. 63, 173 (2006).
34. J. Pardeike and R. H. Müller, Dermal and ocular safety of the new phospholipase A2 inhibitors PX-18 and PX-13 formulated as drug nanosuspension. J. Biomed. Nanotechnol. 5, 437 (2009).
35. W. Yang, J. Fu, T. Wang, and N. He, Chitosan/sodium tripolyphosphate nanoparticles: Preparation, characterization and application as drug carrier. J. Biomed. Nanotechnol. 5, 591 (2009).
36. D. Prajakta, J. Ratnes, K. Chandan, S. Suresh, S. Grace, V. Meera, and P. Vandana, Curcumin loaded pH-sensitive nanoparticles for the treatment of colon cancer. J. Biomed. Nanotechnol. 5, 445 (2009).
37. P. Wu, X. He, K. Wang, W. Tan, C. He, and M. Zheng, A novel methotrexate delivery system based on chitosan-methotrexate covalently conjugated nanoparticles. J. Biomed. Nanotechnol. 5, 557 (2009).
38. D. R. Zhang, T. W. Tan, L. Gao, W. F. Zhao, and P. Wang, Preparation of azithromycin nanosuspensions by high pressure homogenization and its physicochemical characteristics studies. Drug Dev. Ind. Pharm. 33, 569 (2007).
39. 2 nanoparticles in cell culture medium. Colloids Surf., B 68, 83 (2009).
40. M. P. Kumar, Y. M. Rao, and S. Apte, Formulation of nanosuspensions of albendazole for oral administration. Curr. Nanosci. 4, 53 (2008).
41. D. Horn and J. Rieger, Organic nanoparticles in the aqueous phase-theory, experiment and use. Angew Chem. Int. Ed. 40, 4330 (2001).
42. B. Rabinow, Nanosuspensions in drug delivery, nature rev. Drug Discovery 3, 785 (2004).
43. R. H. Müller, C. Jacobs, and O. Kayser, Nanosuspensions as particulate drug formulations in therapy. Rationale for development and what we can expect for the future. Adv. Drug Deliv. Rev. 47, 3 (2001).
44. Y. Hemar and D. S. Horne, A diffusing wave spectroscopy study of the kinetics of Ostwald ripening in protein-stabilised oil: Water emulsions. Colloids Surf., B 12, 239 (1999).
45. W. J. Wu and G. H. Nancollas, A new understanding of the relationship between solubility and particle size. J. Solution Chem. 27, 521 (1998).
46. V. Teeranachaideekul, V. B. Junyaprasert, E. B. Souto, and R. H. Müller, Development of ascorbylpalmitate nanocrystal applying the nanosuspension technology. Int. J. Pharm. 354, 227 (2008).
47. S. Onoue, H. Takahashi, Y. Kawabata, Y. Seto, J. Hatanaka, B. Timmermann, and S. Yamada, Formulation design and photochemical studies on nanocrystal solid dispersion of curcumin with improved oral bioavailability. J. Pharm. Sci. 99, 1871 (2010).
48. D. Duchêne and G. Ponchel, Bioadhesion of solid oral dosage forms, why and how? Eur. J. Pharm. Biopharm. 44, 15 (1997).
49. N. Venkatesan, K. Uchino, K. Amagase, Y. Ito, N. Shibata, and K. Takada, Gastrointestinal patch system for the delivery of erythropoietin. J. Controlled Release 111, 19 (2006).
50. P. Ma, X. W. Dong, C. L. Swadley, A. Gupte, M. Leggas, H. C. Ledebur, and R. J. Mumper, Development of idarubicin and doxorubicin solid lipid nanoparticles to overcome Pgp-mediated multiple drug resistance in leukemia. J. Biomed Nanotechnol. 5, 151 (2009).
51. N. Hussain, V. Jaitley, and A. T. Florence, Recent advances in the understanding of uptake of micro-particulates across the gastrointestinally mphatics. Adv. Drug Deliv. Rev. 50, 107 (2001).
52. J. K. Vasir, K. Tambwekar, and S. Garg, Bioadhesive microspheres as a controlled drug delivery system. Int. J. Pharm. 255, 13 (2003).